FDA Urged to Accelerate Approvals for Rare Disease Treatments

An opinion piece emphasizes the necessity for the FDA to expedite regulatory pathways for therapies targeting rare diseases. The current pace of drug approvals is considered insufficient given the unmet medical needs in rare disorders, prompting calls for balancing rigorous evaluation with risk tolerance to facilitate timely patient access. Accelerated frameworks are posited as critical to fostering innovation in orphan drug development.